SCHEDULE: Vanguard Group Reports 0% Stake in Relay Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Relay Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 5 to Schedule 13G for Relay Therapeutics Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the Common Stock of Relay Therapeutics Inc.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is an administrative update regarding The Vanguard Group's internal reporting structure and does not reflect a change in investment sentiment or the operational performance of Relay Therapeutics Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Relay Therapeutics Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that this filing primarily reflects an administrative change in how The Vanguard Group reports its beneficial ownership across its various entities, rather than a strategic investment decision related to Relay Therapeutics Inc. This type of internal realignment and disaggregated reporting is a procedural matter for large asset managers and does not inherently signal a change in investment thesis for the underlying company.

Stakeholder Impact

• Shareholders of Relay Therapeutics Inc. will see a change in the reported beneficial ownership by The Vanguard Group, Inc. as a single entity, though underlying holdings by Vanguard's subsidiaries may persist and be reported separately.
• This administrative change is unlikely to have a direct material impact on employees, customers, suppliers, or creditors of Relay Therapeutics Inc.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Vanguard Group, Relay Therapeutics, Common Stock, SEC Filing, Institutional Ownership, Internal Realignment